Welcome, Guest. Please login or register.
July 14, 2024, 12:01:59 am

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 34
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 34
Total: 34


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Promising Early Results for Treatment to Gain Functional Control of Hep B  (Read 8741 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Researchers have seen promising early results in a trial of two nucleic acid polymers among people with e-antigen-negative hepatitis B virus who had not been treated for HBV before, Medscape reports. These results suggest that the treatments may lead to functional control of hep B.
Scientists conducted a randomized open-label trial of 40 people with HBV who were new to treatment for the virus. The participants did not have hepatitis C or D viruses (HCV/HDV) or HIV, had serum hep B surface antigen levels above 1,000, hep B viral loads above 7,500 and mild to moderate fibrosis of the liver; none had cirrhosis.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.